Drugs / RALPANCIZUMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01720537 | Jul 2012 → Oct 2013 | hyperlipidemia | Pfizer | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RALPANCIZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137352 ↗ |
| Known as | PF-05335810 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01720537 ↗ |
| Known as | RN-317 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137352 ↗ |
| Action | Inhibit | “Subtilisin/kexin type 9 inhibitor” CHEMBL3137352 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3137352 ↗ |
| Route | Subcutaneous | “Single SC Injection” NCT01720537 ↗ |
| Target | PCSK9 | “Subtilisin/kexin type 9 inhibitor” CHEMBL3137352 ↗ |